The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
Open accessAbstract
OBJECTIVES: To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine. DESIGN: Systematic review and meta-analysis including unpublished data. DATA SOURCES: Bibliographic databases (Medline, Embase, PsycINFO, BIOSIS, and Cochrane Library), clinical trial registries, trial results databases, and regulatory authority websites up until February 2009, as well as unpublished data from the manufacturer of reboxetine (Pfizer, Berlin). ELIGIBILITY CRITERIA: Double blind, randomised, controlled trials of acute treatment (six weeks or more) with reboxetine versus placebo or SSRIs in adults with major depression. OUTCOME MEASURES: Remission and response rates (benefit outcomes), as well as rates of patients with at least one adverse event and withdrawals owing to adverse events (harm outcomes). DATA EXTRACTION AND DATA SYNTHESIS: The procedures for data extraction and assessment of risk of bias were always conducted by one person and checked by another. If feasible, data were pooled by meta-analyses (random effects model). Publication bias was measured by comparing results of published and unpublished trials. RESULTS: We analysed 13 acute treatment trials that were placebo controlled, SSRI controlled, or both, which included 4098 patients. Data on 74% (3033/4098) of these patients were unpublished. In the reboxetine versus placebo comparison, no significant differences in remission rates were shown (odds ratio 1.17, 95% confidence interval 0.91 to 1.51; P=0.216). Substantial heterogeneity (I(2)=67.3%) was shown in the meta-analysis of the eight trials that investigated response rates for reboxetine versus placebo. A sensitivity analysis that excluded a small inpatient trial showed no significant difference in response rates between patients receiving reboxetine and those receiving placebo (OR 1.24, 95% CI 0.98 to 1.56; P=0.071; I(2)=42.1%). Reboxetine was inferior to SSRIs (fluoxetine, paroxetine, and citalopram) for remission rates (OR 0.80, 95% CI 0.67 to 0.96; P=0.015) and response rates (OR 0.80, 95% CI 0.67 to 0.95; P=0.01). Reboxetine was inferior to placebo for both harm outcomes (P<0.001 for both), and to fluoxetine for withdrawals owing to adverse events (OR 1.79, 95% CI 1.06 to 3.05; P=0.031). Published data overestimated the benefit of reboxetine versus placebo by up to 115% and reboxetine versus SSRIs by up to 23%, and also underestimated harm. CONCLUSIONS: Reboxetine is, overall, an ineffective and potentially harmful antidepressant. Published evidence is affected by publication bias, underlining the urgent need for mandatory publication of trial data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Advanced methods in meta‐analysis: multivariate approach and meta‐regression
van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1040 · Cited by 1,580
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546
Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16043-1 · Cited by 1,058
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Cited by
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
Greenland, S., Senn, S. J., Rothman, K. J., Carlin, J. B., Poole, C., Goodman, S. N., & Altman, D. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0149-3 · Cited by 3,200
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
Shi, L., & Lin, L. (2019) · Medicine · doi:10.1097/md.0000000000015987 · Cited by 818
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“The NRI reboxetine was found in a meta-analysis by Eyding et al. (2010) (that included unpublished data by the manufacturer Pfi zer) not signifi cantly more effective than placebo.”
MethodMeader, N., King, K., Llewellyn, A., Norman, G., Brown, J., Rodgers, M., Moe-Byrne, T., Higgins, J. P., Sowden, A., & Stewart, G. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-82 · Cited by 610
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub3 · Cited by 594
The Hong Kong Principles for assessing researchers: Fostering research integrity
Moher, D., Bouter, L., Kleinert, S., Glasziou, P., Sham, M. H., Barbour, V., Coriat, A.-M., Foeger, N., & Dirnagl, U. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000737 · Cited by 540
Empirical Comparison of Publication Bias Tests in Meta-Analysis
Lin, L., Chu, H., Murad, M. H., Hong, C., Qu, Z., Cole, S. R., & Chen, Y. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4425-7 · Cited by 464
Murad, M. H., Montori, V. M., Ioannidis, J. P. A., Jaeschke, R., Devereaux, P. J., Prasad, K., Neumann, I., Carrasco-Labra, A., Agoritsas, T., Hatala, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.5559 · Cited by 454
Uher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010094 · Cited by 418
Murad, M. H. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.001 · Cited by 386
Neuraminidase inhibitors for preventing and treating influenza in adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer, E. A., Onakpoya, I. J., Mahtani, K. R., Nunan, D., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub4 · Cited by 382
Publication bias: What are the challenges and can they be overcome?
Joober, R., Schmitz, N., Annable, L., & Boksa, P. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120065 · Cited by 382
The importance of norepinephrine in depression
Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373
“A recent publication 49 suggests, however, that there may be considerable publication bias and that if unpublished studies are also considered, the antidepressant activity is unclear.”
Assessing risk of bias due to missing results in a synthesis
Page, M. J., Higgins, J. P., & Sterne, J. A. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch13 · Cited by 402
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Golder, S., Loke, Y. K., Wright, K., & Norman, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002127 · Cited by 277
Schmucker, C., Schell, L. K., Portalupi, S., Oeller, P., Cabrera, L., Bassler, D., Schwarzer, G., Scherer, R. W., Antes, G., von Elm, E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114023 · Cited by 269
Considering bias and conflicts of interest among the included studies
Boutron, I., Page, M. J., Higgins, J. P., Altman, D. G., Lundh, A., Hróbjartsson, A., & on behalf of the Cochrane Bias Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch7 · Cited by 258
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
Hart, B., Lundh, A., & Bero, L. (2012) · BMJ · doi:10.1136/bmj.d7202 · Cited by 255
Resting state networks in major depressive disorder
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2014.10.003 · Cited by 218
McCabe, C., & Mishor, Z. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.05.051 · Cited by 184
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Wieseler, B., Kerekes, M. F., Vervoelgyi, V., McGauran, N., & Kaiser, T. (2012) · BMJ · doi:10.1136/bmj.d8141 · Cited by 129
Self-citationCarter, G. C., Cantrell, R. A., Zarotsky, V., Haynes, V. S., Phillips, G., Alatorre, C. I., Goetz, I., Paczkowski, R., & Marangell, L. B. (2012) · Depression and Anxiety · doi:10.1002/da.21918 · Cited by 109
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
Musini, V. M., Lawrence, K. A., Fortin, P. M., Bassett, K., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007066.pub3 · Cited by 98
Yeung, A. S., Jing, Y., Brenneman, S. K., Chang, T. E., Baer, L., Hebden, T., Kalsekar, I., McQuade, R. D., Kurlander, J., Siebenaler, J., et al. (2012) · Depression and Anxiety · doi:10.1002/da.21983 · Cited by 74
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.008 · Cited by 67
A review of the adverse effects and safety of noradrenergic antidepressants
Whiskey, E., & Taylor, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113492027 · Cited by 64
Treatment of Depression in Individuals with Autism Spectrum Disorder: A Systematic Review
Menezes, M., Harkins, C., Robinson, M. F., & Mazurek, M. O. (2020) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2020.101639 · Cited by 55
Cardiovascular adverse effects of newer antidepressants
Mago, R., Tripathi, N., & Andrade, C. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.908709 · Cited by 54
Hodkinson, A., Dietz, K. C., Lefebvre, C., Golder, S., Jones, M., Doshi, P., Heneghan, C., Jefferson, T., Boutron, I., & Stewart, L. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0766-x · Cited by 49
Pringle, A., McCabe, C., Cowen, P., & Harmer, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112474523 · Cited by 37
Treanor, L., Frank, R. A., Cherpak, L. A., Dehmoobad Sharifabadi, A., Salameh, J.-P., Hallgrimson, Z., Fabiano, N., McGrath, T. A., Kraaijpoel, N., Yao, J., et al. (2020) · European Radiology · doi:10.1007/s00330-019-06568-z · Cited by 38
Zou, C. X., Becker, J. E., Phillips, A. T., Garritano, J. M., Krumholz, H. M., Miller, J. E., & Ross, J. S. (2018) · Trials · doi:10.1186/s13063-018-2957-0 · Cited by 36
Assessing the robustness of results from clinical trials and meta-analyses with the fragility index
Lin, L., Xing, A., Chu, H., Murad, M. H., Xu, C., Baer, B. R., Wells, M. T., & Sanchez-Ramos, L. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.08.053 · Cited by 35
Missing clinical trial data: setting the record straight
Godlee, F., & Loder, E. (2010) · BMJ · doi:10.1136/bmj.c5641 · Cited by 34
Warren, J. B. (2020) · BMJ · doi:10.1136/bmj.m3200 · Cited by 30
Shinohara, K., Tajika, A., Imai, H., Takeshima, N., Hayasaka, Y., & Furukawa, T. A. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12502 · Cited by 29
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2016) · Focus · doi:10.1176/appi.focus.140202 · Cited by 20
Potthast, R., Vervölgyi, V., McGauran, N., Kerekes, M. F., Wieseler, B., & Kaiser, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092067 · Cited by 20
Self-citation
Metadata
- Authors
- Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-10-12
- Volume
- 341
- Issue
- oct12 1
- Pages
- c4737-c4737
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2126194308
- Cited by
- 588
- References
- 45
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.